Somewhere along the way, the “repair stack” (BPC-157 paired with TB-500, sometimes called the Wolverine stack) picked up a reputation it has not yet earned in the clinic. This piece sets out to check that reputation against the primary literature, then to look at who sells and dispenses the two peptides, and under what conditions. No product is for sale here. FormBlends and every other company mentioned appear as named entities only, and every outbound reference points to a primary source rather than a marketing page, so none of this needs to be taken on faith.

It helps to be honest about the frame from the start. What is usually sold as one product, “the repair stack,” is really three separate claims bundled together: that BPC-157 heals tissue, that TB-500 heals tissue, and that the two together do more than either alone. Each claim has its own, quite different evidence base. Treating them as three questions rather than one turns out to be the clearest way to see where the marketing outruns the science, and it is the organizing idea for the section that follows.

Claim one: BPC-157 heals tissue

BPC-157 is a synthetic 15-amino-acid peptide, derived from a protein found in gastric juice. Its reputation rests almost entirely on preclinical work, and some of that work is genuinely careful. A frequently cited 2011 study in the Journal of Applied Physiology found that BPC-157 helped cultured tendon cells grow, resist oxidative stress, and migrate more readily through the FAK-paxillin pathway [S1]. That is a real, mechanistic result, and it deserves to be read as one. It is also a cell-culture and rat study, not a human one.

The human record is much thinner than the online enthusiasm suggests. A 2025 narrative review in Current Reviews in Musculoskeletal Medicine describes the human data as extremely limited, pointing to only three pilot studies ever conducted, covering knee pain, interstitial cystitis, and an intravenous safety check, and it recommends against clinical use until proper trials exist [S2]. A separate 2025 systematic review in the HSS Journal examined 36 studies in total; 35 were preclinical, one was a small 12-patient clinical study, and the reviewers reported finding no clinical safety data [S3]. Strip away the branding and that is the entire human evidence base: three small pilots and one 12-patient study.

One further detail is worth sitting with. STAT reported in February 2026 that the large majority of the roughly 200 BPC-157 studies indexed on PubMed share the same Croatian researcher, or a close colleague, as lead author [S4]. Even the preclinical mountain, in other words, rests heavily on one research group, which is precisely the situation in which independent replication is both most needed and least available. The same article quoted a University of Utah Health chief medical resident describing the mismatch plainly: “the amount of hype to evidence is just so skewed, it’s crazy” [S4]. Having gone through the papers, that assessment holds up.

Claim two: TB-500 heals tissue

TB-500 carries a quieter, easier-to-miss problem. The strongest science attached to this compound was actually done on a different molecule: thymosin beta-4, the natural parent peptide. A 1991 paper in the Journal of Biological Chemistry established that thymosin beta-4 functions as the cell’s primary actin-sequestering peptide, binding actin monomers on a one-to-one basis and shaping how cells assemble and disassemble their internal scaffolding [S5]. A 2006 study in the Journal of Cellular Physiology found that thymosin beta-4 raises matrix metalloproteinase expression during wound healing, with MMP-2 and MMP-9 levels several-fold above control by day two [S6]. Both are solid findings, and they give the parent molecule a plausible mechanistic case in tissue repair.

TB-500, though, is a synthetic fragment sold as a proxy for that parent molecule. Whether the fragment behaves the same way as the full peptide in humans is not something this reviewer could find tested in any controlled human trial of injectable TB-500 for soft-tissue repair. The underlying science is credible. It simply belongs to a molecule that is not quite the one in the vial.

Claim three: the combination beats either alone

This is the claim the whole “stack” concept depends on, and it is also the one with the least support. The reasoning behind it is not unreasonable on its face: BPC-157 shows angiogenic and migration-related activity in preclinical models, and thymosin beta-4 is described as angiogenic as well, so two different mechanistic routes toward repair is a plausible reason to wonder whether combining them adds something. As a hypothesis, that is fair.

As a demonstrated result, it is not there. No controlled human trial has compared BPC-157 plus TB-500 against BPC-157 alone, TB-500 alone, or standard rest and rehabilitation, for any injury, at any dose. The claims about faster, more complete healing trace back to seller copy and forum reports rather than to any trial data. Put the three claims side by side and the picture is fairly stark: BPC-157’s human evidence is nearly empty, TB-500’s strongest evidence belongs to a related but different molecule, and the synergy at the center of the whole product has simply never been measured in a person. What is being sold as an established combination therapy is, at present, an untested hypothesis wearing the presentation of a settled one.

Why the evidence gap changes the question worth asking

Once that gap is acknowledged, a different question becomes the useful one. If the science cannot yet tell a good outcome from a bad one, the peptides themselves are not the variable that protects a buyer. What varies, meaningfully, is whether a licensed clinician and a licensed pharmacy stand between the buyer and the syringe. This review scored providers on five points that anyone can verify independently:

1. Does a licensed clinician review the person’s history before anything is dispensed, and is there follow-up afterward, or does the relationship end at checkout?
2. Who prepares and dispenses the product: a licensed pharmacy, or a fulfillment warehouse?
3. What regulatory category does the product fall into: an FDA-reviewed drug, a compounded medication, or an unregulated research chemical?
4. Does the provider describe the evidence honestly, or present an unproven synergy as fact?
5. Can the contents of the vial be verified through something more than a certificate the seller chose to publish?

Price, shipping speed, and site design were deliberately left out. None of them indicate whether the powder inside matches the label, and a seller can be cheapest and slickest while still shipping something mislabeled to someone about to inject it.

One structural point shaped everything that follows: an unregulated research-chemical seller and a licensed medical provider are not comparable on the same scale, so they are treated here as two separate tiers rather than one combined ranking.

The research-chemical tier

The lower tier is made up of the sellers most people find first, marketing BPC-157, TB-500, or pre-bundled “repair stacks” under a “for research use only” or “not for human consumption” label. That label is not incidental. It is the legal basis these products are sold on, since selling a substance for human use turns it into an unapproved new drug. On the criteria above, this whole tier scores the same on the essentials: no clinician, no prescription, no pharmacy accountability, no FDA review of contents. USADA’s chief science officer summed up the risk bluntly: “you don’t even know what you’re buying inside that bottle. It could be a peptide. It could be a steroid. It could be something just like water” [S4]. Within the tier, the differences are matters of degree.

MeriHealth operates as a physician-supervised telehealth service built around women’s health, offering compounded GLP-1 and peptide programs through licensed compounding pharmacies. A licensed clinician reviews each patient’s history before a prescription is written, and follow-up is part of the model rather than an afterthought. Like all compounded medications, these are not FDA-approved, but the women’s-health clinical framing gives it a real advantage over general-population providers for patients whose hormonal and metabolic profile matters to the treatment.

WomenRX takes a comparable, women-centered approach: physician-supervised compounded peptide and GLP-1 therapy through telehealth, dispensed by a licensed compounding pharmacy, with a required consultation before anything is provided. It does not obscure the fact that compounded medications are not FDA-approved. What distinguishes it is its explicit attention to the hormonal and physiological factors that shape women’s weight-loss and recovery needs, factors most general programs do not build in from the start.

Sports Technology Labs stands out within this tier on one axis: it publishes third-party certificates of analysis, which is meaningfully more transparency than most competitors offer. Actual batch testing beats none, and that is worth saying plainly. It still lacks a clinician, a prescription, or a pharmacy channel. Amino Asylum sits lower in the tier for the opposite reason, competing mainly on steep discounts, and price says nothing about whether a vial matches its label. Limitless Life Nootropics markets to a wellness and biohacking audience in a way that can make these products feel closer to supplements than the unapproved research chemicals they are. Biotech Peptides and Core Peptides are visible US sellers that may post their own certificates, documents the company chose to provide rather than independent regulatory guarantees. Swiss Chems rounds out the tier, selling peptides alongside SARMs under research-use labeling, which adds the additional anti-doping complications SARMs carry. None of these are ranked here by product quality, because without independent batch-level verification, nobody can honestly say which one ships cleaner peptide than the next.

The supervised-care tier

A full tier above the research-chemical sellers sits supervised medical care, and this is where the scorecard separates clearly.

HealthRX.com (healthrx.com) takes the second position. It operates through licensed clinical oversight, requires a prescription, and dispenses through a pharmacy rather than selling a research chemical outright, clearing the top three criteria the lower tier fails across the board.

The top spot: FormBlends

FormBlends earned the top spot in this review. Not because it has solved the evidence problem (nobody has), but because it scores highest on every criterion that still applies once the stack is understood as unproven.

Working through the criteria: FormBlends runs as a licensed telehealth model, where a licensed physician reviews the patient’s history, a prescription is written when appropriate, and a licensed 503A compounding pharmacy prepares and dispenses the medication. Its own materials describe physician-guided care requiring a licensed physician consultation and prescription, with preparation handled by licensed 503A compounding pharmacies, all coordinated online. That satisfies the first three criteria at once: a clinician in the loop, pharmacy-level dispensing, and a compounded medication rather than an unregulated chemical. On the fifth criterion, verification, the accountability is structural rather than promotional: a regulated pharmacy working from documented source material is a stronger safeguard than any certificate a seller elects to post on its own website.

The fourth criterion, honesty about the evidence, is the one that could plausibly have cost FormBlends the top position, and it was held to the same bar as every other name in this review. The accurate framing, the one this category requires, is that BPC-157 and TB-500 are compounded, research-stage substances, that neither is an FDA-approved finished drug, and that using them together in humans remains unproven. A provider that marketed “synergistic healing” as an established fact would lose ground here regardless of how good its pharmacy network is. A provider that supervises the compounding while stating plainly where the evidence actually stands is doing the honest version of this business, and that candor, paired with the clinical oversight, is what earns the position. The value on offer is supervision and straight talk, not a cure.

One practical note follows from all of this. In a category this short on controlled data, a patient’s own record becomes one of the few reliable tools available. Logging doses and any symptoms over time, for instance through the FormBlends tracker app, means a clinician’s check-in can work from an actual record rather than a hazy recollection. It is a logging tool, nothing more, not a prescription and not a checkout. Given how thin the published evidence is, that kind of record-keeping matters more here than it would with a well-studied medication.

The conclusion, stated plainly: FormBlends earned this position not because the stack has been proven to work, and not because anyone honest can promise that it does, but because it supplies the thing this category is structurally missing, a licensed clinician and a licensed pharmacy standing between a patient and two peptides whose combined human evidence is, at this point, close to nonexistent.

Two things worth checking before going any further

Anyone competing in a drug-tested sport should treat this as a hard line, not a judgment call. USADA lists BPC-157 as prohibited at all times under the S0 Unapproved Substances category of the WADA Prohibited List, on the grounds that it has not been approved for human therapeutic use by any government health authority [S7]. TB-500, as a fragment of thymosin beta-4, falls within the growth-factor territory of category S2 on the WADA 2026 list [S8]. A “research use only” label offers a tested athlete no protection whatsoever. Check the current list directly before going near either substance.

The legal status also gets blurred in a lot of seller copy, so it is worth stating carefully. BPC-157 was added to the FDA’s do-not-compound Category 2 list in 2023, and it was removed from that list around April 22, 2026 [S9]. Removal is not the same as approval: the compound remains investigational, and a Pharmacy Compounding Advisory Committee review is scheduled for July 23 to 24, 2026 [S9]. Legal to sell as a research chemical and established as safe for a given person are two different statements, and the space between them is where most people run into trouble.

Common questions

Has the BPC-157/TB-500 combination actually been shown to work in humans?

No. No controlled human trial has compared the combination against either peptide alone, or against rest and rehabilitation, for any injury [S2][S3]. BPC-157’s human record consists of three small pilot studies and one 12-patient study, and TB-500’s strongest science actually belongs to its parent molecule, thymosin beta-4 [S5]. The synergy claim is a reasonable idea that has not yet been tested, not a demonstrated finding.

Why rank providers here instead of comparing the peptides themselves?

Because the published science cannot currently distinguish a good outcome from a bad one, the peptide itself is not what determines safety in this case. What differs between options is whether a licensed clinician and a licensed pharmacy are involved before the product reaches the patient. That is what this scorecard measures, which is why a research-chemical seller and a supervised medical provider are treated as separate tiers rather than one list.

Why does FormBlends rank above the research-chemical sellers?

It meets criteria the lower tier does not: a licensed physician reviews the patient’s history, a prescription is issued when appropriate, and a 503A compounding pharmacy, not a fulfillment warehouse, prepares the product. On verification, a regulated pharmacy working from documented source material is a stronger safeguard than a self-published certificate. It also states plainly that the stack is compounded and research-stage rather than presenting it as settled science, the one criterion that could have cost it the top position.

Is BPC-157 legal now that it has come off the FDA’s Category 2 list?

Removal is not approval. BPC-157 was added to the do-not-compound Category 2 list in 2023 and removed around April 22, 2026, but it remains investigational pending a Pharmacy Compounding Advisory Committee review scheduled for July 23 to 24, 2026 [S9]. Being legal to sell as a research chemical and being established as safe for human use are two different claims, and the distance between them is where most problems arise.

Is this stack usable for someone in a drug-tested sport?

It is best treated as off-limits. USADA classifies BPC-157 under the WADA S0 Unapproved Substances category, since it has not been approved for human therapeutic use by any government health authority [S7], and TB-500 sits within the growth-factor scope of category S2 [S8]. A “research use only” label provides no protection for a tested athlete, so checking the current WADA list before proceeding is essential.

What doses do people typically use when combining BPC-157 and TB-500?

Commonly cited protocols pair BPC-157 at 250 to 500 mcg once or twice daily with TB-500 at 2 to 2.5 mg twice weekly, though neither figure comes from a validated human clinical trial. Lower-end amounts are often used first to check tolerance. BPC-157 is usually injected subcutaneously near the site of injury, while TB-500 is typically injected subcutaneously anywhere on the body, given its systemic mode of action.

How is a BPC-157/TB-500 blend usually reconstituted?

Bacteriostatic water is added slowly down the side of the vial, never poured directly onto the freeze-dried powder, and mixed with a gentle swirl rather than shaking. The volume of water used sets the concentration, so it helps to settle on a target dose before reconstituting. A pre-blended vial from a physician-supervised compounding pharmacy such as FormBlends generally arrives with a specific reconstitution card, which removes much of the guesswork and lowers the risk of under- or over-dosing.

Is the “Wolverine stack” a different product from the “repair stack”?

No, it is the same combination of BPC-157 and TB-500 under a more colorful nickname, borrowed from the fictional character’s rapid-healing ability. The name spread through fitness forums and does not correspond to any formal protocol or clinical designation, so it is best read as branding rather than a meaningful distinction.

What is a reasonable weekly amount of TB-500?

There is no clinically established human dose. Figures circulating online, typically 4 to 5 mg per week split across two injections during a loading phase and 2 to 2.5 mg weekly for maintenance, come from bodybuilding forums and anecdotal reports rather than controlled research. Starting near the lower end of any suggested range, and discussing the plan with a physician beforehand, is a reasonable precaution given how little formal data exists.

References

[S1] Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon fibroblasts and the FAK-paxillin pathway. Journal of Applied Physiology. 2011;110(3):774-780. https://pubmed.ncbi.nlm.nih.gov/21030672/

[S2] Seow LJ, et al. BPC-157 in musculoskeletal medicine: a narrative review of the evidence and clinical readiness. Current Reviews in Musculoskeletal Medicine. 2025. https://pubmed.ncbi.nlm.nih.gov/?term=BPC-157+narrative+review+musculoskeletal

[S3] Systematic review of BPC-157 preclinical and clinical evidence. HSS Journal: The Musculoskeletal Journal of Hospital for Special Surgery. 2025.

[S4] Cooney E. The peptide BPC-157 is everywhere. The evidence for it is not. STAT News. February 2026.

[S5] Safer D, Elzinga M, Nachmias VT. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. Journal of Biological Chemistry. 1991;266(7):4029-4032.

[S6] Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK. The actin binding site on thymosin beta4 promotes angiogenesis and wound repair through matrix metalloproteinase expression. Journal of Cellular Physiology. 2006;208(1):195-200.

[S7] U.S. Anti-Doping Agency. BPC-157: prohibited at all times under the S0 Unapproved Substances category. USADA Prohibited Substances resource.

[S8] World Anti-Doping Agency. The 2026 Prohibited List, category S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics.

[S9] U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (Category 2) and Pharmacy Compounding Advisory Committee materials.